troglitazone has been researched along with gw 7845 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanchard, SG; Brackeen, MF; Brown, KK; Cobb, JE; Collins, JL; Harrington, WW; Hashim, MA; Henke, BR; Hull-Ryde, EA; Kaldor, I; Kliewer, SA; Lake, DH; Leesnitzer, LM; Lehmann, JM; Lenhard, JM; Miller, JF; Mook, RA; Noble, SA; Oliver, W; Orband-Miller, LA; Parks, DJ; Plunket, KD; Szewczyk, JR; Willson, TM | 1 |
| Blanchard, SG; Boswell, EG; Brown, KK; Charifson, PS; Cobb, JE; Collins, JL; Cooper, JP; Dezube, M; Henke, BR; Hull-Ryde, EA; Lake, DH; Lenhard, JM; Oliver, W; Oplinger, J; Parks, DJ; Pentti, M; Plunket, KD; Tong, WQ | 1 |
| Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
| Chen, YE; Fu, M; Lin, Y; Mao, Z; Zhang, J; Zhu, X | 1 |
| Chen, YE; Fu, M; Lin, Y; McLntee, FL; Xiao, H; Zhang, J; Zhu, X | 1 |
1 review(s) available for troglitazone and gw 7845
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
4 other study(ies) available for troglitazone and gw 7845
| Article | Year |
|---|---|
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
Topics: Administration, Oral; Aminopyridines; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Lipids; Male; Mice; Oxazoles; Propionates; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Stereoisomerism; Structure-Activity Relationship; Transcription Factors; Transfection; Tyrosine | 1998 |
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
Topics: Administration, Oral; Animals; Benzoates; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Lipids; Male; Mice; ortho-Aminobenzoates; Oxazoles; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Solubility; Structure-Activity Relationship; Transcription Factors; Tyrosine | 1998 |
Thiazolidinediones, a class of anti-diabetic drugs, inhibit Id2 expression through a PPARgamma-independent pathway in human aortic smooth muscle cells.
Topics: Anilides; Aorta; Chromans; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Regulation; Humans; Hypoglycemic Agents; Inhibitor of Differentiation Protein 2; Muscle, Smooth, Vascular; Oxazoles; Receptors, Cytoplasmic and Nuclear; Repressor Proteins; RNA, Messenger; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Troglitazone; Tyrosine | 2003 |
Interferon regulatory factor-1 mediates PPARgamma-induced apoptosis in vascular smooth muscle cells.
Topics: Adenoviridae; Animals; Aorta; Apoptosis; Cells, Cultured; Chlorocebus aethiops; Chromans; DNA-Binding Proteins; Dose-Response Relationship, Drug; Gene Expression Regulation; Humans; Interferon Regulatory Factor-1; Ligands; Muscle, Smooth, Vascular; Oxazoles; Phosphoproteins; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; RNA Stability; RNA, Messenger; Thiazolidinediones; Time Factors; Transcription Factors; Troglitazone; Tyrosine; Up-Regulation | 2004 |